✦ LIBER ✦

147: Drug Utilization and Cost Considerations of Erythropoietic Stimulating Agents in Chronic Kidney Disease Patients not Receiving Dialysis

✍ Scribed by Samir Mody; Francis Vekeman; Antoine Gosselin; Brahim Bookhart; R. Scott McKenzie; Patrick Lefebvre

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

130: Drug Utilization and Cost Considera

✍ François Laliberté; Patrick Lefebvre; Francis Vekeman; Janice Lopez; R. Scott Mc 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 186 KB

140: Assessment of Drug Utilization Patt

✍ Patrick Lefebvre; François Laliberté; Marie-Héléne Lafeuille; Brahim Bookhart; R 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 196 KB

PUK15 DRUG UTILIZATION AND COSTS OF ERYT

✍ P Lefebvre; MS Duh; F Laliberte; RS Mckenzie; S Mody; B Bookhart; CT Piech 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

DU6 ASSESSMENT OF DRUG UTILIZATION PATTE

✍ MH Lafeuille; P Lefebvre; B Bookhart; F Laliberte; R Bailey; M Corral; CT Piech 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB

PUK9 SEVEN YEAR TRENDS OF PHARMACY BENEF

✍ F Vekeman; RA Bailey; F Laliberté; M Senbetta; RS McKenzie; P Lefebvre 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

Dosing patterns and costs of erythropoie

✍ Mei Sheng Duh; Samir H. Mody; R. Scott McKenzie; Patrick Lefebvre; Antoine Gosse 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 619 KB